DECAMP-1: Diagnosis and Surveillance of Indeterminate Pulmonary Nodules



Status:Recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:45 - Any
Updated:11/1/2018
Start Date:January 2013
End Date:December 2019
Contact:Avrum Spira, MD
Email:aspira@bu.edu

Use our guide to learn which trials are right for you!

Detection of Early Lung Cancer Among Military Personnel Study 1 (DECAMP-1): Diagnosis and Surveillance of Indeterminate Pulmonary Nodules

The goal is to improve the efficiency of the diagnostic follow-up of patients with
indeterminate pulmonary nodules by determining whether biomarkers for lung cancer diagnosis
that are measured in minimally invasive biospecimens are able to distinguish malignant from
benign pulmonary nodules that are incidentally detected in high-risk smokers.

The Detection of Early lung Cancer Among Military Personnel (DECAMP) consortium is a
multidisciplinary and translational research program that includes 7 Veterans Administration
Hospitals (VAH), the 4 designated Military Treatment Facilities (MTF) and 4 academic
hospitals as clinical study sites, several molecular biomarker laboratories, along with
Biostatics, Bioinformatics, Pathology and Biorepository cores. The DECAMP Coordinating Center
will facilitate rapid selection, design and execution of clinical studies within this
multi-institutional consortium. The goal will be accomplished by recruiting 500 smokers with
indeterminate pulmonary nodules (0.7cm - 3.0cm) on chest CT who will undergo fiberoptic
bronchoscopy and will be followed for 2 years until a final diagnosis is made. The diagnostic
performance of four previously established lung cancer biomarkers in this cohort will be
validated; 1) a gene-expression biomarker measured in bronchial airway brushings; 2) a
proteomic signatures measured in bronchial airway biopsies; 3) a proteomic signature measured
in serum; and 4) a signature of serum cytokines. The added value of the molecular markers to
clinical and imaging markers routinely used in the diagnostic work up of these patients and
develop an integrated model (i.e. clinical, imaging & molecular markers) that results in the
most robust diagnostic predictor will be evaluated.

Inclusion Criteria:

- 45 years of age or older;

- Initial diagnosis of indeterminate pulmonary nodule (0.7-3.0 cm);

- Smoking status: Current or former smoker with ≥ 20 pack years (pack years = number of
packs per day X number of years smoked)

- Willing to undergo fiberoptic bronchoscopy;

- Able to tolerate all biospecimen collection as required by protocol;

- Able to comply with standard of care follow up visits including clinical exams,
diagnostic work-ups, and imaging for a minimum of two years;

- Able to fill out Patient Lung History questionnaire;

- Willing and able to provide a written informed consent.

Exclusion Criteria:

- History or previous diagnosis of lung cancer;

- Diagnosis of pure ground glass opacities on chest CT;

- Contraindications to nasal brushing or fiberoptic bronchoscopy including ulcerative
nasal disease, hemodynamic instability, severe obstructive airway disease, unstable
cardiac or pulmonary disease; inability to protect airway or altered level of
consciousness;

- Allergies to any local anesthetic that may be used to obtain biosamples in the study.
We found this trial at
15
sites
8901 Rockville Pike
Bethesda, Maryland 20889
(301) 295-4000
Principal Investigator: Robert Browning, MD
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
620 John Paul Jones Cir
Portsmouth, Virginia 23708
(757) 953-5008
Principal Investigator: Jonas Carmichael, MD
Naval Medical Center - Portsmouth Naval Medical Center Portsmouth, Virginia has proudly served the military...
?
mi
from
Portsmouth, VA
Click here to add this to my saved trials
34800 Bob Wilson Dr,
San Diego, California 92134
(619) 532-6400
Principal Investigator: John S Parrish, MD
Naval Medical Center - San Diego We are the largest and most comprehensive military healthcare...
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Boston, Massachusetts
Principal Investigator: Ronald Goldstein, MD
?
mi
from
Boston, MA
Click here to add this to my saved trials
1 Boston Medical Center Place
Boston, Massachusetts 02118
617.638.8000
Principal Investigator: Ehab Billatos, MD
Boston University Medical Center Boston Medical Center is an extraordinary community of health care providers...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Buffalo, New York
Principal Investigator: Mary Reid, PhD
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Dallas, Texas
Principal Investigator: John Battaile, MD
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denver, Colorado
Principal Investigator: Robert Keith, MD
?
mi
from
Denver, CO
Click here to add this to my saved trials
Los Angeles, California
Principal Investigator: Steven Dubinett, MD
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90024
Principal Investigator: Steve Dubinett, MD
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Nashville, Tennessee
Principal Investigator: Pierre Massion, MD
?
mi
from
Nashville, TN
Click here to add this to my saved trials
3900 Woodland Avenue
Philadelphia, Pennsylvania 19104
Principal Investigator: Anil Vachani
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Anil Vachani, MD
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15240
Principal Investigator: Charles Atwood, MD
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
San Antonio, Texas
Principal Investigator: Michael Morris, MD
?
mi
from
San Antonio, TX
Click here to add this to my saved trials